NCT07389174
Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
At risk: Primary completion moved at least 10 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jan 2027 to Dec 2027 Show 4 more changesShow less
- Start date: Feb 2026 to Jun 2027
- Eligibility criteria expanded, about 7 words
- Study completion pushed from Jun 2027 to Dec 2028
- Secondary endpoints: details revised at 1 of 5 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (5)
Arms and interventions
Participants with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). Participants in this arm receive standard-of-care endocrine therapy alone.
Participants with high-volume metastatic hormone-sensitive prostate cancer (mHSPC). High volume is defined as the presence of visceral metastases or ≥ 4 bone lesions with ≥ 1 beyond the vertebral bodies and pelvis. Participants in this arm receive oral LC-K76 combined with standard-of-care endocrine therapy.
Participants with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). Low volume is defined as ≤ 3 bone metastases confined to the vertebral bodies and pelvis, and no visceral metastases. Participants in this arm receive oral LC-K76 combined with standard-of-care endocrine therapy.
Participants with low-volume metastatic hormone-sensitive prostate cancer (mHSPC). Participants in this arm receive standard-of-care endocrine therapy alone.
Drugs: Standard Endocrine Therapy
Dietary supplements: LC-K76
Sites
1 site in 1 country
- Changzheng hospitalShanghai, Shanghai Municipality, China